 Cisplatin combination chemotherapy elderly patients urothelial tumours proportion cancer patients curative therapy declines chronological age Between January January patients years median combination chemotherapy Eighteen patients cycles adjuvant chemotherapy median drop creatinine clearance rate ml/min ml/min patients alive evidence disease whole group median survival months dose intensity cisplatin recurrence Eighteen patients metastatic disease objective response cycles median patients alive free disease group significant kidney damage dose intensity cisplatin predict response Treatment significant sepsis rate patients withdrew treatment toxicity cisplatin combination chemotherapy treatment-related death efficacy similar patients Age patients potential benefit therapy important cause reduced benefit chemotherapy elderly patients reduced dosage cisplatin